Fresh analysis reveals that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who stop conventional diet and exercise regimens.
Findings released in a prominent health publication demonstrates that while overweight people can lose substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals buying these treatments need to be informed of the risk of rapid weight regain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment weight in about 18 months.
Weighing Approaches
The analysis, which examined dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Scientists point out that individuals who lose weight through diet and exercise generally see a slower weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Doctors believe the mechanism of the drugs accounts for the accelerated weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
Health authorities advise the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, considering the significant potential of weight regain, the therapy is often ongoing.
This view is reinforced by drug manufacturers, who state that the results "underscore the chronic character of excess weight," similar to managing conditions like diabetes.
Patient Accounts
People who have discontinued the medication explain a powerful resurgence of appetite.
"It felt as if a switch that goes on and you're instantly ravenous," recalled a patient.
This challenge is worsened if individuals have not developed permanent dietary or behavioural changes during treatment.
Growing Use
Survey data show that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Use is more common among females compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, researchers caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic solution and lasting health benefits hinges on combined behavioural changes.
